Results: In patients presenting with new lung findings without a history of carcinoma (n ‫؍‬ 37), the sensitivity and specificity of PET was 95% and 82%, respectively. In this population, the negative predictive value was 93% and the positive predictive value was 86%. PET was less sensitive and specific for evaluating metastatic or recurrent disease in patients previously treated for carcinoma. In patients presenting with a previously treated primary lung cancer (n ‫؍‬ 13), the sensitivity of PET was 70%, with a specificity of 67%. The negative predictive value was only 40% and the positive predictive value was 88% in this subset of patients. In patients with an extrapulmonary primary carcinoma presenting with new lung nodules (n ‫؍‬ 21), the sensitivity and specificity of PET was 92% and 63%, respectively. In this population, the negative predictive value was 83% while the positive predictive value was 80%. Of the 71 total cases for which follow-up data were available, there were 5 false-negative cases and 7 false-positive cases, for an overall sensitivity of 88%, specificity of 75%, negative predictive value of 81%, and positive predictive value of 84%. Conclusions: The sensitivity of PET is highest for the evaluation of new malignancy in patients without a known primary carcinoma. PET is less sensitive for evaluating metastatic or recurrent disease.
T he role of positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) in the evaluation of lung malignancy is currently being defined. Reports [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] have shown a high sensitivity (90 to 100%) and specificity (76 to 100%) for the evaluation of malignancy in patients presenting with new lung findings. Patz et al 1 established the use of cutoff values of 2.5 for the standardized uptake ratio (SUR), noting that in their study, a SUR Ͻ 2.5 had a 100% specificity for benign lesions that were Ն 1.2 cm. Another study 2 suggested an equal sensitivity and specificity for lesions as small as 7 mm. Many of these studies were designed to specifically address the performance of PET scanning in the evaluation of solitary pulmonary nodules in patients without a history of carcinoma. [3] [4] [5] [6] [7] A few studies 8, 9 have evaluated the performance of PET scanning in diagnosing metastatic cancer or recurrent lung cancer in pa-tients with a previously treated carcinoma, presenting with new lung nodules. Given the high sensitivity and negative predictive value reported in these studies, some authors have suggested that PET evaluation demonstrating hypermetabolic activity in the location of the lesion in question, with an SUR of Ͻ 2.5, is adequate to diagnose a benign nodule. According to this approach, these patients could be managed with follow-up imaging and biopsy of the nodule could thus be avoided. 10 -12 Anecdotal experience in our institution suggested a higher false-negative and false-positive rate than has been published in the literature. We therefore decided to test the accuracy of PET scanning in a tertiary-care hospital with an active PET referral center.
Materials and Methods
We retrospectively reviewed the database of our hospital for all patients referred to our institution from the period of April 1997 through August 1999 for PET evaluation of any new lung abnormalities. Only patients presenting with new lung findings, either nodule or mass, or abnormal parenchymal opacities were evaluated. All patients included in our analysis had nodules ranging in size from 7 to 30 mm (measured on CT using lung algorithm windows). Patients with isolated pleural effusions or pleural abnormalities were not included in the study. Patients being evaluated for staging of a known lung carcinoma or mesothelioma were not included in our study. This study was approved by our institutional review board.
One hundred ninety-six patients referred for PET met criteria for inclusion in the study. The patients were classified into one of three categories: (1) patients without a history of carcinoma presenting with new lung nodule or mass (n ϭ 94); (2) patients with prior resection/treatment of lung carcinoma with new or changing lung findings worrisome for recurrent or metastatic disease (n ϭ 51); and (3) patients with a known extrapulmonary primary carcinoma presenting with new lung nodules (n ϭ 51).
PET Imaging
All subjects fasted at least 4 h prior to the examination and had a documented normal serum glucose level prior to injection of FDG. PET imaging was performed approximately 60 to 90 min after IV administration of a dose of 4.218 megabecquerel/kg of FDG, according to department protocol, which is similar to the protocol used by other investigators for tumor studies. 13 Multiple partially overlapping scans of 12.8 cm were obtained from the lung apices through the pelvis using a scanner (PENN-PET 240H; UGM Medical Systems; Philadelphia, PA). The scanner has an intrinsic resolution of 5.5 mm in all three planes at the center of the field of view and operates without septa. Transmissions scans were obtained at the conclusion of the study for nonuniform attenuation correction over the chest (Fig 1) .
PET Data Analysis
Imaging processing was done on a workstation (Ultra 60; Sun Microsystems; Palo Alto, CA). Image reconstruction was performed using the ordered subset expectation maximization algorithm. 13 An SUR was performed for all abnormal lesions by drawing a region of interest around the lesion in question. These calculations relate activity found in the lesion to the dose injected and the patient body mass: SUR ϭ mean PET counts/pixel/ second ϫ calibration factor/injected dose (millicuries)/body weight (kilograms), where the calibration factor ϭ (microcuries/ milliliters)/(counts/pixel/second).
In the majority of cases, CT examination demonstrating the lesion in question was available at the time of study interpretation Figure 1 . Top: Whole-body PET scan from a patient with known breast cancer, after mastectomy, presenting with multiple bilateral pulmonary nodules, ranging in size from 4 to 15 mm. There is prominent cardiac uptake. Bowel activity is also noted. Note the lack of focal pulmonary uptake. Middle: CT scan demonstrating one of the lesions in question in the right upper lobe of the lung. The lesion measured 1.4 cm. Bottom: Corresponding axial PET scan at same level does not demonstrate foci of abnormal increased activity in the right lung. There is increased cardiac uptake, as well as slightly increased uptake along the left lateral chest wall at the site of her breast tumor. and the PET scan was interpreted in conjunction with the CT. Visual analysis, as well as calculation of the SUR for the dominant lesion identified by PET and/or lesion seen on CT, was performed by two experienced readers as part of the clinical interpretation. Lesions demonstrating increased uptake with respect to the mediastinum were considered abnormal. A cutoff SUR value of 2.5 was used to establish benignity. 1 A focus of high FDG activity (SUR Ͼ 2.5) was considered positive for malignancy. If the patient presented with multiple nodules, visual analysis and SUR, if possible, were performed for the dominant lesion identified on CT, as well as for any lesion demonstrating abnormal increased metabolic activity on visual inspection.
Attenuation-corrected scans were available in all cases. Attenuated and nonattenuated PET images, as well as the SUR were taken into account for the final interpretation.
Follow-up
Follow-up was obtained primarily via a questionnaire that was sent to all referring physicians. Specifically, we asked if histopathology or follow-up imaging was obtained, and if treatment with surgery, radiation, and/or chemotherapy was initiated. In addition, a review of the pathology reports and charts of the patients referred from within our own hospital was performed. Only patients in whom the diagnosis of malignancy or benignancy was established were included in our final analysis. Malignancy or benignancy was established if patients had definitive pathology of the lesion in question. If histopathology was not obtained, the diagnosis of malignancy was established if follow-up imaging demonstrated interval disease progression (range, 3 months to 3.5 years) A benign condition was established if follow-up imaging demonstrated lesion regression with a minimum 6-month interval or lesion stability for a minimum of 1 year.
Statistical Analysis
Sensitivity and specificity of PET were determined by comparing the results from PET scan with the histologic findings, if available, or with patient survival and follow-up imaging demonstrating disease progression, regression, or stability.
Results
Malignancy or benignancy was established in 71 patients, of whom 46 had pathologic diagnosis of the lesion in question, and 24 had follow-up imaging demonstrating disease progression, regression or stability. One additional patient had histology obtained at autopsy. Overall, 60% of the patients (43 of 71 patients) presented with a single pulmonary lesion. The remaining 40% (28 of 71 patients) presented with multiple bilateral pulmonary nodules (range, 2 to Ն 20).
Overall, of the 71 patients with definitive diagnosis, there were five false-negative cases and seven false-positive cases, for an overall sensitivity of 88% and a specificity of 75%. The overall negative predictive value for all patients presenting with an abnormality in the lungs is 81% ( Table 1 ). The breakdown of histologic subtypes for false-positive and false-negative results is included in Table 2 .
New Lung Nodules in Patients Without a History of Carcinoma
The diagnosis of malignancy or a benign condition was established in 37 of 94 patients evaluated for new isolated lung nodule(s) or mass with no history of carcinoma. Of these, histology was obtained in 23 patients and follow-up imaging was obtained in 14 patients. PET correctly diagnosed a malignant process in 19 of 37 patients (true-positive) and a benign process in 14 of 37 patients (true-negative).
There was one false-negative result in a patient who presented with a 1.5-cm nodule in the right lower lobe noted on CT, in which both visual qualitative inspection and semiquantitative analysis of PET scan demonstrated no metabolically active process within the chest. The lesion was resected because of high clinical suspicion; histology demonstrated adenocarcinoma of the lung. No lymph nodes were positive for malignancy (Table 3) .
There were three false-positive PET results in this group of patients. In all cases, the lesion in question demonstrated an SUR Ͼ 2.5. Two of the falsepositive cases were due to biopsy-proven Mycobacterium avium-intracellulare (MAI) and sarcoid. The third patient presented with multiple bilateral pulmonary nodules on CT. PET examination demonstrated intense focal uptake in the posterior left lung that corresponded to a lesion seen on CT, as well as focal intense uptake in the left hilar region, thought to represent local lymph node metastasis. The other nodules did not demonstrate abnormal increased uptake. The patient refused biopsy; however, retrospective review of outside films obtained prior to the CT, followed by imaging every 6 months for 2 years demonstrated lesion stability. The overall sensitivity of PET for the evaluation of malignancy in this population was 95%, with a specificity of 82% and negative predictive value of 93% (Table 4) .
New Lung Nodules in Patients With a History of an Extrapulmonary Primary Carcinoma
Fifty-one patients with a known extrapulmonary primary carcinoma presented for the evaluation of possible pulmonary metastasis. The breakdown of the patients' primary carcinomas is listed in Table 5 . Definitive diagnosis of a malignant or benign condition was established in 21 of these patients. Of these, histologic diagnosis was obtained in 12 patients, and follow-up imaging was obtained in 8 patients. One additional patient died during stem-cell transplant for germ-cell carcinoma; autopsy demonstrated pulmonary metastasis, consistent with findings on PET scan.
In this population, PET correctly identified malignancy in 12 patients and a benign pulmonary process in 5 patients. There was one false-negative study in a patient with primary breast carcinoma who presented with bilateral pulmonary nodules ranging in size from 4 to 15 mm. Visual inspection of the PET scan did not demonstrate any foci of abnormal uptake within the lungs, suggesting a benign etiology. Semiqualitative analysis was therefore not performed. Follow-up CT in 3 months demonstrated an increase in both size and number of pulmonary nodules; the patient subsequently developed brain metastasis within 1 year (Table 3) . There were three false-positive results in this population. In all three cases, the patients presented with a single lung nodule/mass. PET scan demonstrated abnormal increased glucose uptake (SUR Ͼ 2.5) in all three cases, suggesting a metastatic process. In all three cases, the lesion in question was resected. In two cases, histology demonstrated nonspecific inflammatory change (one patient had primary squamous cell carcinoma of the penis; the other patient had primary adenocarcinoma of the colon). In the third case, histology was consistent with a hamartoma in a patient with a primary liver hepatoma.
Overall, PET scan had a sensitivity of 92% and a specificity of 63% in evaluating potential metastasis in patients with a known extrapulmonary primary carcinoma. The negative predictive value of PET scan in this population is 83% (Table 6 ).
New Pulmonary Abnormalities in Patients With Treated Lung Cancer
Definitive diagnosis was established in 13 patients with a previously resected lung primary who were now being evaluated for new or changing lung findings worrisome for possible recurrence (n ϭ 4) or new pulmonary metastasis (n ϭ 9). All patients were at least 5 months postresection and/or chemotherapy and radiation at the time of referral for PET scan (range, 5 months to 9 years). Histology was obtained in 12 patients, and follow-up imaging was definitive in 1 patient. The PET scan correctly identified malignancy in 7 of the 13 patients, and a benign process in 2 patients (Table 7) .
However, in 3 of the 13 patients, PET incorrectly suggested a benign process (false-negative), all of who had histologic diagnosis indicating metastatic or recurrent disease. One patient being evaluated for recurrence in the region of the primary carcinoma presented with enlarging soft-tissue mass in the right apex, in the region of prior resection and radiation therapy 1.5 years prior. Another patient presented with a 1.5-cm nodule in the contralateral lung from her primary lung cancer, as well as several smaller bilateral nodules. The third patient presented with bilateral lower lobe nodules approximately 1.0 to 1.5 cm in size. In all cases, the PET scan did not demonstrate any focal FDG uptake within the lungs on visual analysis. Semiquantitative analysis was therefore not performed. Wedge resection of the nodules in the patients demonstrated recurrent squamous cell carcinoma in one patient, and recurrent adenocarcinoma of the lung in the other two patients (Table 3) .
There was a single false-positive result in this patient population. The patient had been treated with radiation approximately 6 months prior, and was now being evaluated for an enlarging pulmonary soft-tissue mass suggesting possible recurrence vs radiation change. The PET scan demonstrated hypermetabolic uptake in the region of CT abnormality (SUR Ͼ 2.5), suggesting recurrent tumor. Subsequent follow-up imaging with CT every 6 months for 1.5 years demonstrated stability and eventual decrease in size of the abnormal soft tissue, compatible with benign radiation changes.
In this population, PET demonstrated a sensitivity of 70%, with a specificity of 67% and a negative predictive value of only 40% (Table 8) . Follow-up data were not available in 124 patients because the primary referring physician did not respond to the questionnaire, could not be located, or did not provide adequate information in response to the questionnaire.
Discussion
In our population, the overall sensitivity and specificity of PET scan for the evaluation of lung malignancy for all patient groups was 88% and 75%, respectively. In particular, PET was most accurate in patients without a history of carcinoma, in whom the sensitivity of PET was 95% and the specificity was 82%. This is similar to what is reported in the literature for PET evaluation of solitary pulmonary nodules (sensitivity, 82 to 100%; specificity, 75 to 100%). [3] [4] [5] [6] [7] In our study, false-positive results occurred in patients with an active inflammatory process, such as sarcoid or MAI infection. In each case, the SUR was Ͼ 2.5, which is above the cutoff for a benign lesion as established by Patz et al 1 ; however, visual analysis of the lesions suggested that although uptake within the lesions was greater than uptake in the mediastinum, it was not as high as is normally seen in malignant disease.
Our study is in contradiction to the findings of Knight et al, 8 who found a similar sensitivity of 100% in patients with or without a history of malignancy. Like Patz et al, 1 Knight et al 8 demonstrated no false-negative results for lesions Ͼ 1.0 cm in either patient population group using a cutoff level of SUR Ͼ 2.5 for malignancy. In our study, however, patients with a treated extrapulmonary primary carcinoma or primary lung carcinoma demonstrated a lower sensitivity (92% and 70%, respectively) and specificity (63% and 67%, respectively) for evaluating metastatic and/or recurrent disease. Furthermore, in our population, false-negative results occurred in patients in whom visual analysis failed to even demonstrate a region of increased FDG uptake at the site of the lesion in question, so a region of interest or SUR could not be calculated. In addition, Knight et al 8 demonstrated a higher accuracy for evaluation of malignancy in patients with a history of malignancy (95%) than in patients with new lung nodules (81%). This is opposite to what we observed in our study. Our study appears to confirm the findings of Hubner et al, 7 who demonstrated a lower sensitivity (83 to 87%) of PET in evaluating lung recurrence or metastatic disease when compared to solitary pulmonary nodules (sensitivity, 100%). However, unlike Hubner et al, 7 who reported a similar specificity of 80 to 83% in patients with a history of any carcinoma when compared to those without a history of carcinoma, we noted a lower specificity (63 to 67%) of PET in patients with a history of carcinoma.
In the literature, false-negative results have been documented 14, 15 for bronchoalveolar lung cancer, which are typically slow growing tumors and may not demonstrate a hypermetabolic state. Therefore, it is notable that in our study, false-negative lesions occurred in cases where the histology confirmed adenocarcinoma (three cases) and squamous cell carcinoma (one case), which typically are hypermetabolic tumors. In all four cases, the tumor was approximately 1.5 cm in size. In one case, the patient had no known primary carcinoma; the lesion was believed to represent a new lung primary. In the other three cases, the patients had been previously treated for a primary lung tumor and were presenting with new pulmonary nodules after treatment. Tables 1, 3 for expansion of abbreviations.
Frequently, small lesion size (Ͻ 1.2 cm) is cited as a reason for a lower sensitivity of PET. The use of SUR Ͼ 2.5 as a cutoff for benign lesions was established using lesions that were at least 1.2 cm in size. 1 Subsequent studies 4, 6, 12 have reported a high sensitivity and specificity for lesions as small as 7 mm in size when combined qualitative visual analysis and semiquantitative SUR values are implemented. Furthermore, a recent study by Lowe and Naunheim 12 found that the sensitivity and specificity of PET was not statistically different when comparing nodules 7 mm to 1.5 cm in size with nodules Ͼ 1.5 cm, when lesions were analyzed with both qualitative visual inspection and a SUR cutoff of 2.5. However, in our study, the five false-negative cases occurred when the lesion in question was at least 1.2 to 1.5 cm in size, which is within the resolution of our PET camera. In all five false-negative cases, PET failed to show any hypermetabolic uptake, so an SUR value could not be calculated. This was seen in four cases of metastatic disease (primary breast [n ϭ 1], squamous cell of the lung [n ϭ 1], and adenocarcinoma of the lung [n ϭ 2]), and one case of newly diagnosed primary adenocarcinoma of the lung (Table 3) . We speculate that this may be related in part to a slower metabolic rate in metastatic lesions when compared with a primary carcinoma.
A recent study from our institution using dual time point FDG-PET imaging has shown promising results in differentiating between malignant and benign nodules (A. Matthies, MD; unpublished data; June 2000). We are currently reviewing our data to determine whether the use of dual time point imaging may improve both sensitivity and specificity in evaluating patients presenting with pulmonary nodules worrisome for metastatic or recurrent disease after treatment with chemotherapy and/or radiation.
A potential criticism of our study was the relatively short interval follow-up in several cases. Ideally, an imaging follow-up interval of 2 years is considered definitive for benignity. However, in all cases with short interval (Ͻ 1 year) follow-up, the lesion in question had either regressed or resolved and was therefore considered benign, or had demonstrated significant growth and subsequent progression in lesion size or number of nodules, and thus considered malignant.
A second potential criticism of our study is the relatively small number of cases; follow-up data were available in only 71 cases. However, to our knowledge, this is still the largest study to date and represents the largest number of cases.
Conclusion
Our study confirms reports in the literature suggesting that PET has a high sensitivity of 95% and negative predictive value of 93% in evaluating new lung nodules in patients without a history of carcinoma. [3] [4] [5] [6] [7] In our study, however, PET is less reliable in assessing pulmonary metastasis (sensitivity, 70 to 92%; specificity, approximately 65%) in patients with a prior carcinoma. PET was least accurate in the evaluation of patients with a primary lung cancer and possible recurrent or metastatic disease.
